Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 ProteinsChristopher M. Bartley MD, PhD, Thomas T. Ngo BS, Le Duy Do PhD, Anastasia Zekeridou MD, PhD, Ravi Dandekar BS, MS, Sergio Muñiz-Castrillo MD, PhD, Bonny D. Alvarenga BA, Kelsey C. Zorn BA, MHS, Asritha Tubati BS, Anne-Laurie Pinto MSc, Weston D. Browne BS, Patrick W. Hullett MD, PhD, Mark Terrelonge MD, MPH, Ryan D. Schubert MD, Amanda L. Piquet MD, Binxia Yang PhD, Mayra Montalvo MD, Andrew F. Kung BA, Sabrina A. Mann BS, Maulik P. Shah MD, MHS, Michael D. Geschwind MD, PhD, Jeffrey M. Gelfand MD, MAS, Joseph L. DeRisi PhD, Sean J. Pittock MD, Jérôme Honnorat MD, PhD, Samuel J. Pleasure MD, PhD, Michael R. Wilson MD, PhD
Annuls of Neurology, 2023Abstract: Objective- Co-occurring anti-tripartite motif-containing protein 9 and 67 autoantibodies (TRIM9/67-IgG) have been reported in only a very few cases of paraneoplastic cerebellar syndrome. The value of these biomarkers and the most sensitive methods of TRIM9/67-IgG detection are not known.
Methods- We performed a retrospective, multicenter study to evaluate the cerebrospinal fluid and serum of candidate TRIM9/67-IgG cases by tissue-based immunofluorescence, peptide phage display immunoprecipitation sequencing, overexpression cell-based assay (CBA), and immunoblot. Cases in which TRIM9/67-IgG was detected by at least 2 assays were considered TRIM9/67-IgG positive.
